Compare · BIAF vs CRL
BIAF vs CRL
Side-by-side comparison of bioAffinity Technologies Inc. (BIAF) and Charles River Laboratories International Inc. (CRL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIAF and CRL operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- CRL is the larger of the two at $14.42B, about 3156.1x BIAF ($4.6M).
- BIAF has been more active in the news (20 items in the past 4 weeks vs 8 for CRL).
- CRL has more recent analyst coverage (25 ratings vs 0 for BIAF).
- Company
- bioAffinity Technologies Inc.
- Charles River Laboratories International Inc.
- Price
- $3.70-7.50%
- $300.23-2.04%
- Market cap
- $4.6M
- $14.42B
- 1M return
- -58.66%
- -
- 1Y return
- -92.75%
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- 2000
- News (4w)
- 20
- 8
- Recent ratings
- 0
- 25
Charles River Laboratories International Inc.
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets and chemical compounds through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company was founded in 1947 and is based in Wilmington, Massachusetts.
Latest BIAF
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- SEC Form PRER14A filed by bioAffinity Technologies Inc.
- SEC Form 8-K filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
- SEC Form 424B5 filed by bioAffinity Technologies Inc.
- WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Latest CRL
- Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
- Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
- SEC Form 4 filed by Charles River Laboratories International Inc.
- Charles River and Autolomous Partner to Transform Laboratory Execution Systems
- EVP & Chief Financial Officer Coleman Glenn bought $2,974 worth of shares (10 units at $297.43), increasing direct ownership by 0.04% to 27,762 units (SEC Form 4)
- UBS resumed coverage on Charles River with a new price target
- Charles River Laboratories International Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Charles River Highlights Refreshed Strategic Vision to Drive Profitable Growth and Long-Term Value Creation at 2026 Investor Day
- Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
- Charles River Laboratories to Present at Morgan Stanley and Baird Conferences